Inflammatory myofibroblastic tumor(IMT)is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate.Diagnostic challenges arise from the diverse pathological pre...Inflammatory myofibroblastic tumor(IMT)is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate.Diagnostic challenges arise from the diverse pathological presentation,variable symptomatology,and lack of different imaging features.However,IMT is identified by the fusion of the anaplastic lymphoma kinase(ALK)gene,which is present in approximately 70%of cases,with various fusion partners,including ran-binding protein 2(RANBP2),which allows confirmation of the diagnosis.While surgery is the preferred approach for localized tumors,the optimal long-term treatment for advanced or metastatic disease is difficult to define.Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT.Crizotinib,an ALK tyrosine kinase inhibitor(TKI),was officially approved by the US Food and Drug Administration(FDA)in 2020 to treat IMT with ALK rearrangement.However,most patients face resistance and disease progression,requiring consideration of sequential treatments.Combining radiotherapy with targeted therapy appears to be beneficial in this indication.Early promising results have also been achieved with immunotherapy,indicating potential for combined therapy approaches.However,defined recommendations are still lacking.This review analyzes the available research on IMT,including genetic disorders and their impact on the course of the disease,data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication,as well as summarizing general knowledge about prognostic and predictive factors,also in terms of resistance to systemic therapy.展开更多
Anti-inflammatory compounds,delivered as a payload to the gastrointestinal tract(GIT)by carriers,still cannot treat inflammatory bowel diseases without avoid-ing side effects.Here,we developed payload-free protein nanop...Anti-inflammatory compounds,delivered as a payload to the gastrointestinal tract(GIT)by carriers,still cannot treat inflammatory bowel diseases without avoid-ing side effects.Here,we developed payload-free protein nanoparticles(PNPs)that crossed GIT to retain in the colon and treat colitis by restoring intestinal bar-rier integrity by modulating gut microbiome and metabolome.Specifically,PNPs,orally administered to mice with acute colitis,reached the colon within three hours.Consequently,PNPs improve gut microbiota dysbiosis to reverse metabolism bal-ance,suppressing the expression of tumor-necrosis factorαand toll-like receptor 4 that restores the intestinal barrier integrity.PNPs then ameliorated colon inflam-mation and attenuated gut microbiota dysbiosis by exerting probiotic effects on gut microbiota,treating colitis in a week more effectively than the clinically often used 5-aminosalicylic acid without causing undesired side effects.Such PNPs repre-sent safe,sustainable,and cost-effective therapeutics for treating inflammatory and metabolic diseases by eliminating microbial and metabolomic imbalance.展开更多
Efficient strategies for transforming Bacillus subtilis vegetative cells into spores(BtS transformation)are still limited,although they show promise for the treatment of inflammatory bowel disease(IBD).A novel,simple,an...Efficient strategies for transforming Bacillus subtilis vegetative cells into spores(BtS transformation)are still limited,although they show promise for the treatment of inflammatory bowel disease(IBD).A novel,simple,and rapid photo-induced BtS transformation mechanism is now presented that utilizes a novel aggregation-induced emission luminogen(AIEgen)photosensitizer,triphenylamine-benzothiadiazole-pyridine-p-tolylboronic acid bromine salt(TBPBB),that generates reactive oxygen species(ROS)when exposed to light.The ROS selectively target and damage the membranes of Bacillus subtilis and trigger their transformation into spores.These spores demonstrate considerable promise for the effective treatment of IBD in a mouse disease model.Furthermore,thefluorescence signal generated by TBPBB can be used to directly visualize the recovery of damaged intestinal tis-sue.This is a valuable tool for monitoring the healing process and gaining insights into therapeutic efficacy.This study highlights the remarkable practical value of AIEgen-induced BtS transformation for identifying,localizing,and visualizing the therapeutic outcomes of IBD treatments.展开更多
目的:探究白芍总苷胶囊联合丁酸氢化可的松乳膏治疗对慢性湿疹患者皮损面积和炎症反应的影响。方法:选取2021年7月-2022年6月于笔者医院接受治疗的80例慢性湿疹患者,采用单双球法随机分为对照组(丁酸氢化可的松乳膏)和联合组(白芍总苷...目的:探究白芍总苷胶囊联合丁酸氢化可的松乳膏治疗对慢性湿疹患者皮损面积和炎症反应的影响。方法:选取2021年7月-2022年6月于笔者医院接受治疗的80例慢性湿疹患者,采用单双球法随机分为对照组(丁酸氢化可的松乳膏)和联合组(白芍总苷胶囊联合丁酸氢化可的松乳膏治疗),各40例。比较治疗前和治疗4周后两组患者临床效果[湿疹面积及严重程度指数(Eczema area and severity index,EASI)、中医证候积分、整体美学改善量表(Global aesthetic improvement scale,GAIS)]、皮肤屏障功能[经皮水分丢失值(Transepidermal water loss,TEWL)、湿度、角质层含水量(Stratum corneum hydration,SCH)]、免疫因子(Th1、Th2、IgE)、炎症因子水平(IL-23、IL-17、IL-1β)。结果:治疗4周后,两组患者EASI评分、中医证候积分、TEWL、Th1、Th2、IgE、IL-23、IL-17及IL-1β水平均较治疗前降低,联合组低于对照组,但GAIS高于对照组(均P<0.05);湿度、SCH较治疗前升高,联合组高于对照组(均P<0.05)。结论:白芍总苷胶囊联合丁酸氢化可的松乳膏能够改善慢性湿疹患者临床症状,提高患者整体美观度,增强患者皮肤屏障功能,改善患者免疫功能,减轻患者炎症反应。展开更多
Background:Since early December 2019,coronavirus disease 2019(COVID-19)has emerged as a global pandemic and public health crisis.This study aims to explore the relationship between cardiac injury and infl ammatory bio...Background:Since early December 2019,coronavirus disease 2019(COVID-19)has emerged as a global pandemic and public health crisis.This study aims to explore the relationship between cardiac injury and infl ammatory biomarkers in patients with severe COVID-19.Methods:We collected data on 91 patients with a confi rmed diagnosis of severe COVID-19 from February 8 to March 31,2020.Demographic characteristics,clinical data,and in-hospital outcomes were compared.The relationship between cardiac injury and infl ammatory biomarkers was analyzed.Logistic regression was used to explore the independent risk factors for cardiac injury.Results:The mean age of all patients was 61 years±14 years.About half of the patients were male.Hypertension and coronary heart disease were more common in the cardiac injury group.The levels of infl ammatory biomarkers in patients who experienced cardiac injury were generally higher than the levels of those without cardiac injury,including interleukin-6,interleukin-2 receptor(IL-2R),procalcitonin,and high-sensitivity C-reactive protein.There were positive correlations between the levels of high-sensitivity troponin I and N-terminal prohormone of brain natriuretic peptide and the levels of infl ammatory biomarkers.Logistic regression shows that IL-2R(odds ratio 1.001,95%confi dence interval 1.000–1.002,P=0.045)and comorbidities(odds ratio 4.909,95%confi dence interval 1.231–19.579,P=0.024)are independent risk factors for cardiac injury in patients with severe COVID-19.Conclusion:High levels of infl ammatory biomarkers are associated with higher risk of cardiac injury in patients with severe COVID-19.IL-2R and comorbidities are predictors of cardiac injury.展开更多
基金National Science Center 2019/35/O/NZ2/03761(AMC)。
文摘Inflammatory myofibroblastic tumor(IMT)is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate.Diagnostic challenges arise from the diverse pathological presentation,variable symptomatology,and lack of different imaging features.However,IMT is identified by the fusion of the anaplastic lymphoma kinase(ALK)gene,which is present in approximately 70%of cases,with various fusion partners,including ran-binding protein 2(RANBP2),which allows confirmation of the diagnosis.While surgery is the preferred approach for localized tumors,the optimal long-term treatment for advanced or metastatic disease is difficult to define.Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT.Crizotinib,an ALK tyrosine kinase inhibitor(TKI),was officially approved by the US Food and Drug Administration(FDA)in 2020 to treat IMT with ALK rearrangement.However,most patients face resistance and disease progression,requiring consideration of sequential treatments.Combining radiotherapy with targeted therapy appears to be beneficial in this indication.Early promising results have also been achieved with immunotherapy,indicating potential for combined therapy approaches.However,defined recommendations are still lacking.This review analyzes the available research on IMT,including genetic disorders and their impact on the course of the disease,data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication,as well as summarizing general knowledge about prognostic and predictive factors,also in terms of resistance to systemic therapy.
基金Zhejiang Provincial Science and Technology Plan,Grant/Award Number:2021C02072-6National Natural Science Foundation of China,Grant/Award Numbers:81911530223,32101095+4 种基金Provincial Key Laboratory Construction Plans,Grant/Award Number:2020E10025Plan of National and Zhejiang Provincial Youth Science and Technology Innovation Leader,Grant/Award Numbers:[2020]366,2018R52021Zhejiang Province Public Welfare Technology Research Plans,Grant/Award Number:LGF21H060008National Key Research and Development Program of China,Grant/Award Number:2023YFF1103900China Agriculture Research System of MOF and MARA。
文摘Anti-inflammatory compounds,delivered as a payload to the gastrointestinal tract(GIT)by carriers,still cannot treat inflammatory bowel diseases without avoid-ing side effects.Here,we developed payload-free protein nanoparticles(PNPs)that crossed GIT to retain in the colon and treat colitis by restoring intestinal bar-rier integrity by modulating gut microbiome and metabolome.Specifically,PNPs,orally administered to mice with acute colitis,reached the colon within three hours.Consequently,PNPs improve gut microbiota dysbiosis to reverse metabolism bal-ance,suppressing the expression of tumor-necrosis factorαand toll-like receptor 4 that restores the intestinal barrier integrity.PNPs then ameliorated colon inflam-mation and attenuated gut microbiota dysbiosis by exerting probiotic effects on gut microbiota,treating colitis in a week more effectively than the clinically often used 5-aminosalicylic acid without causing undesired side effects.Such PNPs repre-sent safe,sustainable,and cost-effective therapeutics for treating inflammatory and metabolic diseases by eliminating microbial and metabolomic imbalance.
基金National Science Foundation of China,Grant/Award Numbers:52003228,52273197Shenzhen Key Laboratory of Functional Aggregate Materials,Grant/Award Number:DSYS20211021111400001Science Technology Innovation Commission of Shenzhen Municipality,Grant/Award Numbers:KQTD20210811090142053,JCYJ20220818103007014,JSGG20220606141800001。
文摘Efficient strategies for transforming Bacillus subtilis vegetative cells into spores(BtS transformation)are still limited,although they show promise for the treatment of inflammatory bowel disease(IBD).A novel,simple,and rapid photo-induced BtS transformation mechanism is now presented that utilizes a novel aggregation-induced emission luminogen(AIEgen)photosensitizer,triphenylamine-benzothiadiazole-pyridine-p-tolylboronic acid bromine salt(TBPBB),that generates reactive oxygen species(ROS)when exposed to light.The ROS selectively target and damage the membranes of Bacillus subtilis and trigger their transformation into spores.These spores demonstrate considerable promise for the effective treatment of IBD in a mouse disease model.Furthermore,thefluorescence signal generated by TBPBB can be used to directly visualize the recovery of damaged intestinal tis-sue.This is a valuable tool for monitoring the healing process and gaining insights into therapeutic efficacy.This study highlights the remarkable practical value of AIEgen-induced BtS transformation for identifying,localizing,and visualizing the therapeutic outcomes of IBD treatments.
文摘目的:探究白芍总苷胶囊联合丁酸氢化可的松乳膏治疗对慢性湿疹患者皮损面积和炎症反应的影响。方法:选取2021年7月-2022年6月于笔者医院接受治疗的80例慢性湿疹患者,采用单双球法随机分为对照组(丁酸氢化可的松乳膏)和联合组(白芍总苷胶囊联合丁酸氢化可的松乳膏治疗),各40例。比较治疗前和治疗4周后两组患者临床效果[湿疹面积及严重程度指数(Eczema area and severity index,EASI)、中医证候积分、整体美学改善量表(Global aesthetic improvement scale,GAIS)]、皮肤屏障功能[经皮水分丢失值(Transepidermal water loss,TEWL)、湿度、角质层含水量(Stratum corneum hydration,SCH)]、免疫因子(Th1、Th2、IgE)、炎症因子水平(IL-23、IL-17、IL-1β)。结果:治疗4周后,两组患者EASI评分、中医证候积分、TEWL、Th1、Th2、IgE、IL-23、IL-17及IL-1β水平均较治疗前降低,联合组低于对照组,但GAIS高于对照组(均P<0.05);湿度、SCH较治疗前升高,联合组高于对照组(均P<0.05)。结论:白芍总苷胶囊联合丁酸氢化可的松乳膏能够改善慢性湿疹患者临床症状,提高患者整体美观度,增强患者皮肤屏障功能,改善患者免疫功能,减轻患者炎症反应。
基金the Beijing Municipal Natural Science Foundation(no.7192078).the Ethics Commission of Beijing Hospital(2020BJYYEC-035-01).
文摘Background:Since early December 2019,coronavirus disease 2019(COVID-19)has emerged as a global pandemic and public health crisis.This study aims to explore the relationship between cardiac injury and infl ammatory biomarkers in patients with severe COVID-19.Methods:We collected data on 91 patients with a confi rmed diagnosis of severe COVID-19 from February 8 to March 31,2020.Demographic characteristics,clinical data,and in-hospital outcomes were compared.The relationship between cardiac injury and infl ammatory biomarkers was analyzed.Logistic regression was used to explore the independent risk factors for cardiac injury.Results:The mean age of all patients was 61 years±14 years.About half of the patients were male.Hypertension and coronary heart disease were more common in the cardiac injury group.The levels of infl ammatory biomarkers in patients who experienced cardiac injury were generally higher than the levels of those without cardiac injury,including interleukin-6,interleukin-2 receptor(IL-2R),procalcitonin,and high-sensitivity C-reactive protein.There were positive correlations between the levels of high-sensitivity troponin I and N-terminal prohormone of brain natriuretic peptide and the levels of infl ammatory biomarkers.Logistic regression shows that IL-2R(odds ratio 1.001,95%confi dence interval 1.000–1.002,P=0.045)and comorbidities(odds ratio 4.909,95%confi dence interval 1.231–19.579,P=0.024)are independent risk factors for cardiac injury in patients with severe COVID-19.Conclusion:High levels of infl ammatory biomarkers are associated with higher risk of cardiac injury in patients with severe COVID-19.IL-2R and comorbidities are predictors of cardiac injury.
